Press release archive

Chiesi Group delivers solid H1 2026 performance, combining growth, continued investment in innovation and positive economic impact across communities

Chiesi advances its Carbon Minimal Inhaler journey as European submissions for its Single Inhaler Triple Therapy (SITT) and ICS/LABA combination next-generation propellant pMDIs are validated

Chiesi receives European Marketing Authorisation for its Single Inhaler Triple Therapy delivered via NEXThaler® for the maintenance treatment of Asthma

Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

Chiesi Group Announces New Chair and Vice Chair

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition

Chiesi Group Selects Salesforce Agentforce Life Sciences to Transform Customer Engagement

Chiesi Global Rare Diseases receives positive CHMP opinion for LOJUXTA® (lomitapide) ▼ Capsules for pediatric use in Homozygous Familial Hypercholesterolemia (HoFH)

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

Chiesi and Bespak partner to advance Carbon Minimal Inhaler production with UK manufacturing site

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU